The work exploits privileged binding of radiolabeled first component of complement (Clq) to antigencomplexed immunoglobulin hg) but not to monomeric Ig, and it applies this reaction to the study of clinical serum or extravascular fluid samples Three recent papers are recommended for further reading.
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Circulating or extravascular-fluid-suspended antigen-antibody complexes (so-called soluble immune complexes or SICs) may occur during the course of a number of idiopathic inflammatory, infectious, renal, hematological, or neoplastic diseases. The conditions under which SICs are found in these diseases are based on widespread, fast, and easy screening tests for SICs, introduced into clinical medicine at the beginning of the last decade. This paper on the radiolabeled Clq binding test (which was subsequently published in a modified version') remains the leading SICdetection assay in many laboratories worldwide. For its original development a number of favourable circumstances coincided: P.H. Lambert's basic idea to convert V. Agnello's discovery of agar-gel precipitation between Cig and immunoglobulin aggregates 2 into a rathoimmunoassay met with H. Gerber's and my perseverance to make the system work in fluid phase; and PA. Miescher's clinical expertise was essential to obtain blood samples from patients with active disease.
The publication of our paper sparked the development of many other test systems for the detection of SICs, so that today numerous different procedures are available, some in the form of commercial test kits. SIC reactants other than Clq have been used (for example, conglutinins, rheumatoid factors, IC-receptor-bearing cells, and monoclonal antibodies) against SIC-bound complement components, but Clq remains the most widely used.
It is remarkable that most knowledge on the pathogenetic properties of SICs was obtained from SIC monitoring of chronic inflammatory diseases characterized by chronically circulating SIC5, rather than from laboratory animal studies of mechanisms of physiological removal of antigens by antibodies, of which the formation of SlCs is a transient physiological consequence. A large body of literature has now accumulated on SICs, but perhaps some of it is occasionally too enthusiastic (the SIC issue in cancer, leukemia, and kidney diseases is not settled); however, sometimes it points to new clinical involvement of SlCs.
Thus, SICs are useful clinical parameters to follow in monitoring such diseases as active systemic lupus erythematosus, rheumatoid arthritis, necrotising vasculitis, and some forms of bacterial or viral diseases (for example, endocarditis or AIDS, especially pediatric AIDS). The levels of the complexes may correlate with clinical activity ofthe disease, and their disappearance upon therapy or removal after plasmapheresis may mean clinical improvement. Research into the molecular composition of SICs may give additional information about the nature of the antigen that chronically affects the host, eluding efficient neutralization and removal by antibodies, It may also provide information about the cause of reticuloendothelial system insufficiency to remove the SICs from circulation and inflammatory sites.
Three recent papers are recommended for further reading.
3 -5 Our work was awarded the Prize of the Swiss Society for Internal Medicine in 1975.
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